Will Midostaurin be officially included in the medical insurance catalog in 2025?

Midostaurin is a therapeutic drug that targets multiple kinase activities. Its main indications are FLT3 mutation-positive acute myeloid leukemia (AML) and systemic mastocytosis (MCL). These two hematological diseases are often limited in efficacy due to high recurrence rates and poor prognosis in traditional treatments. Midostaurin, as a new molecular targeted drug, provides patients with new treatment hope.

InAML treatment, midostaurin is mainly used for patients who carry FLT3-ITD or TKD mutations at the time of initial diagnosis. It is used in combination with traditional chemotherapy to delay disease progression by blocking tumor cell-dependent signal transduction pathways. In mastocytosis, the drug inhibits the activity of the KIT D816V mutant receptor, thereby reducing the number of mast cells, alleviating symptoms, and improving organ function. It is an important part of the current rare disease treatment system.

Although it has long been approved for use by multiple authoritative agencies abroad, such asFDA and EMA, and has been included in relevant medical security systems, in mainland China, the original drug of midostaurin has not yet been officially launched on the market, nor has it been included in the national medical insurance directory. If patients want to use the drug, they usually need to obtain the original version through overseas channels and other medical institutions, which is expensive and carries a heavy out-of-pocket burden. This situation has limited the popularity and clinical use of the drug to a certain extent, causing many patients suitable for this drug to miss the opportunity for timely intervention.

In addition, it is worth noting that with the increasing domestic emphasis on rare diseases and targeted drugs, a variety of innovative drugs including midostaurin are accelerating the review and approval process. If the drug is approved for marketing in China and included in the medical insurance system in the future, it will greatly ease the financial pressure on patients and improve treatment accessibility.

Currently, some patients choose to purchase generic versions of Midostaurin from overseas channels, especially in countries such as India, where a number of reasonably priced, quality-regulated generic versions have been launched, and generic drugs have the advantage of consistent ingredients.

Reference materials:https://go.drugbank.com/drugs/DB06595